In patients with HER2-enriched breast cancer with brain metastasis, the upregulation of xCT (SLC7A11), a cystine/glutamate antiporter facilitating cystine import and glutamate export, was observed (Parida et al., 2022). Here, ERBB2 is linked to breast cancer.